672 related articles for article (PubMed ID: 33510179)
1. Metformin exerts anti-cancerogenic effects and reverses epithelial-to-mesenchymal transition trait in primary human intrahepatic cholangiocarcinoma cells.
Di Matteo S; Nevi L; Overi D; Landolina N; Faccioli J; Giulitti F; Napoletano C; Oddi A; Marziani AM; Costantini D; De Rose AM; Melandro F; Bragazzi MC; Grazi GL; Berloco PB; Giuliante F; Donato G; Moretta L; Carpino G; Cardinale V; Gaudio E; Alvaro D
Sci Rep; 2021 Jan; 11(1):2557. PubMed ID: 33510179
[TBL] [Abstract][Full Text] [Related]
2. The FXR agonist obeticholic acid inhibits the cancerogenic potential of human cholangiocarcinoma.
Di Matteo S; Nevi L; Costantini D; Overi D; Carpino G; Safarikia S; Giulitti F; Napoletano C; Manzi E; De Rose AM; Melandro F; Bragazzi M; Berloco PB; Giuliante F; Grazi G; Giorgi A; Cardinale V; Adorini L; Gaudio E; Alvaro D
PLoS One; 2019; 14(1):e0210077. PubMed ID: 30677052
[TBL] [Abstract][Full Text] [Related]
3. Metformin reverses mesenchymal phenotype of primary breast cancer cells through STAT3/NF-κB pathways.
Esparza-López J; Alvarado-Muñoz JF; Escobar-Arriaga E; Ulloa-Aguirre A; de Jesús Ibarra-Sánchez M
BMC Cancer; 2019 Jul; 19(1):728. PubMed ID: 31337349
[TBL] [Abstract][Full Text] [Related]
4. TGF-β signaling is an effective target to impair survival and induce apoptosis of human cholangiocarcinoma cells: A study on human primary cell cultures.
Lustri AM; Di Matteo S; Fraveto A; Costantini D; Cantafora A; Napoletano C; Bragazzi MC; Giuliante F; De Rose AM; Berloco PB; Grazi GL; Carpino G; Alvaro D
PLoS One; 2017; 12(9):e0183932. PubMed ID: 28873435
[TBL] [Abstract][Full Text] [Related]
5. Mitogen-activated protein kinase kinase kinase 4 deficiency in intrahepatic cholangiocarcinoma leads to invasive growth and epithelial-mesenchymal transition.
Yang LX; Gao Q; Shi JY; Wang ZC; Zhang Y; Gao PT; Wang XY; Shi YH; Ke AW; Shi GM; Cai JB; Liu WR; Duan M; Zhao YJ; Ji Y; Gao DM; Zhu K; Zhou J; Qiu SJ; Cao Y; Tang QQ; Fan J
Hepatology; 2015 Dec; 62(6):1804-16. PubMed ID: 26340507
[TBL] [Abstract][Full Text] [Related]
6. Metformin Exerts Antiproliferative and Anti-metastatic Effects Against Cholangiocarcinoma Cells by Targeting STAT3 and NF-ĸB.
Saengboonmee C; Seubwai W; Cha'on U; Sawanyawisuth K; Wongkham S; Wongkham C
Anticancer Res; 2017 Jan; 37(1):115-123. PubMed ID: 28011481
[TBL] [Abstract][Full Text] [Related]
7. Inhibitory effects of metformin at low concentration on epithelial-mesenchymal transition of CD44(+)CD117(+) ovarian cancer stem cells.
Zhang R; Zhang P; Wang H; Hou D; Li W; Xiao G; Li C
Stem Cell Res Ther; 2015 Dec; 6():262. PubMed ID: 26718286
[TBL] [Abstract][Full Text] [Related]
8. Metformin Inhibits TGF-β1-Induced Epithelial-to-Mesenchymal Transition via PKM2 Relative-mTOR/p70s6k Signaling Pathway in Cervical Carcinoma Cells.
Cheng K; Hao M
Int J Mol Sci; 2016 Nov; 17(12):. PubMed ID: 27916907
[TBL] [Abstract][Full Text] [Related]
9. Metformin inhibits the radiation-induced invasive phenotype of esophageal squamous cell carcinoma.
Nakayama A; Ninomiya I; Harada S; Tsukada T; Okamoto K; Nakanuma S; Sakai S; Makino I; Kinoshita J; Hayashi H; Oyama K; Miyashita T; Tajima H; Takamura H; Fushida S; Ohta T
Int J Oncol; 2016 Nov; 49(5):1890-1898. PubMed ID: 27599468
[TBL] [Abstract][Full Text] [Related]
10. Sulforaphane Potentiates Gemcitabine-Mediated Anti-Cancer Effects against Intrahepatic Cholangiocarcinoma by Inhibiting HDAC Activity.
Tomooka F; Kaji K; Nishimura N; Kubo T; Iwai S; Shibamoto A; Suzuki J; Kitagawa K; Namisaki T; Akahane T; Mitoro A; Yoshiji H
Cells; 2023 Feb; 12(5):. PubMed ID: 36899823
[TBL] [Abstract][Full Text] [Related]
11. Metformin sensitizes EGFR-TKI-resistant human lung cancer cells in vitro and in vivo through inhibition of IL-6 signaling and EMT reversal.
Li L; Han R; Xiao H; Lin C; Wang Y; Liu H; Li K; Chen H; Sun F; Yang Z; Jiang J; He Y
Clin Cancer Res; 2014 May; 20(10):2714-26. PubMed ID: 24644001
[TBL] [Abstract][Full Text] [Related]
12. The H4 histamine receptor agonist, clobenpropit, suppresses human cholangiocarcinoma progression by disruption of epithelial mesenchymal transition and tumor metastasis.
Meng F; Han Y; Staloch D; Francis T; Stokes A; Francis H
Hepatology; 2011 Nov; 54(5):1718-28. PubMed ID: 21793031
[TBL] [Abstract][Full Text] [Related]
13. Metformin inhibits 17β-estradiol-induced epithelial-to-mesenchymal transition via βKlotho-related ERK1/2 signaling and AMPKα signaling in endometrial adenocarcinoma cells.
Liu Z; Qi S; Zhao X; Li M; Ding S; Lu J; Zhang H
Oncotarget; 2016 Apr; 7(16):21315-31. PubMed ID: 26824324
[TBL] [Abstract][Full Text] [Related]
14. Effects of metformin and phenformin on apoptosis and epithelial-mesenchymal transition in chemoresistant rectal cancer.
Park JH; Kim YH; Park EH; Lee SJ; Kim H; Kim A; Lee SB; Shim S; Jang H; Myung JK; Park S; Lee SJ; Kim MJ
Cancer Sci; 2019 Sep; 110(9):2834-2845. PubMed ID: 31278880
[TBL] [Abstract][Full Text] [Related]
15. Histone deacetylase inhibitors promote epithelial-mesenchymal transition in Hepatocellular Carcinoma
Xiao Q; Liu H; Wang HS; Cao MT; Meng XJ; Xiang YL; Zhang YQ; Shu F; Zhang QG; Shan H; Jiang GM
Theranostics; 2020; 10(22):10245-10261. PubMed ID: 32929346
[TBL] [Abstract][Full Text] [Related]
16. Loss of Fbxw7 synergizes with activated Akt signaling to promote c-Myc dependent cholangiocarcinogenesis.
Wang J; Wang H; Peters M; Ding N; Ribback S; Utpatel K; Cigliano A; Dombrowski F; Xu M; Chen X; Song X; Che L; Evert M; Cossu A; Gordan J; Zeng Y; Chen X; Calvisi DF
J Hepatol; 2019 Oct; 71(4):742-752. PubMed ID: 31195063
[TBL] [Abstract][Full Text] [Related]
17. M2-polarized tumor-associated macrophages promote epithelial-mesenchymal transition via activation of the AKT3/PRAS40 signaling pathway in intrahepatic cholangiocarcinoma.
Sun D; Luo T; Dong P; Zhang N; Chen J; Zhang S; Dong L; Janssen HLA; Zhang S
J Cell Biochem; 2020 Apr; 121(4):2828-2838. PubMed ID: 31692069
[TBL] [Abstract][Full Text] [Related]
18. The regulatory effects of metformin on the [SNAIL/miR-34]:[ZEB/miR-200] system in the epithelial-mesenchymal transition(EMT) for colorectal cancer(CRC).
Wang Y; Wu Z; Hu L
Eur J Pharmacol; 2018 Sep; 834():45-53. PubMed ID: 30017802
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of Epithelial-Mesenchymal Transition and Metastasis by Combined TGFbeta Knockdown and Metformin Treatment in a Canine Mammary Cancer Xenograft Model.
Leonel C; Borin TF; de Carvalho Ferreira L; Moschetta MG; Bajgelman MC; Viloria-Petit AM; de Campos Zuccari DA
J Mammary Gland Biol Neoplasia; 2017 Mar; 22(1):27-41. PubMed ID: 28078601
[TBL] [Abstract][Full Text] [Related]
20. Metformin mediated reversal of epithelial to mesenchymal transition is triggered by epigenetic changes in E-cadherin promoter.
Banerjee P; Surendran H; Chowdhury DR; Prabhakar K; Pal R
J Mol Med (Berl); 2016 Dec; 94(12):1397-1409. PubMed ID: 27534967
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
